A study to investigate the comparative efficacy and tolerability of nisoldipine coat-core and atenolol in the treatment of mild to moderate hypertension

British Journal of Clinical Practice

Volumn 50, Issue 7, 1996, Pages 368-372

  Murray, T S ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; NISOLDIPINE;

ADULT; AGED; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; EDEMA; ESSENTIAL HYPERTENSION; FATIGUE; FEMALE; HEADACHE; HEART RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE WEAKNESS; NECK PAIN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; ATENOLOL; CALCIUM CHANNEL BLOCKERS; DOUBLE-BLIND METHOD; FEMALE; GREAT BRITAIN; HEART RATE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; NISOLDIPINE;

EID: 0030481414     PISSN: 00070947     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Opie LH. Clinical Use of Calcium Channel Antagonist Drugs. Boston: Kluwer Academic Publishers, 1990; part V: 219-244.
2. Opie LH. Ed. Drugs for the Heart. 4th edn, Philadelphia :WB Saunders, 1995.
3. Godfraind T. Salomone S. Dessy C et al. Selectivity scale of calcium antagonists in the human cardiovascular system based on in vitro studies. J Cardiol Pharm 1992; 20 (suppl 5); S34-S41.
4. Graefe K-H, Ziegler R. Wingender W et al. Cardiovascular effects of dihydropyridine calcium-channel antagonists and their relation to drug levels in plasma. Ann NY Acad Sei 1988; 522: 628.
5. Kazda S. Garthoff B. Meyer H et al. Pharmacology of a new calcium antagonistic compound, isobutyl methyl 1.4-dihydro-2.6-dimethyl-4-(2nitrophenyl)-3.5-pyridinedicarboxylate (nisoldipine. Bay k 5552). Arzneimittel-Forschung 1980; 30: 2144.
6. ô.Friedel HA, Sorkin EM. Nisoldipine: a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of angina pectoris. hypertension and related cardiovascular disorders. Drugs 1988:36:682.
7. T.Lewis BS. Efficacy and safety of nisoldipine coat-core in the management of angina pectoris. systemic hypertension, and ischaemic ventricular dysfunction. Am J Cardiol 1995; 75: 46E-53E.
8. S.Luus HG. Muller FO. Myburgh DP et al. A multi-centre study to investigate the antihypertensive effect of three single oral daily doses of nisoldipine administered as a new long-acting "coat-core" tablet formulation. SAfrMedJ 1992; 82(6): 458-459.
9. Muller FO, Luus HG, Myburgh DP et al. Ambulatory blood pressure monitoring in mild to moderate hypertension treated with a long acting nisoldipine tablet formulation (Abs). SAfrMedJ 1992; 82(6): 455.
10. Wadworth AN, Murdoch D, Brogden. Atenolol: a reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders. Drugs 1991; 42(3): 468-510.
11. l.Cruickshank JM, McAinsh J. Atenolol and ischaemic heart disease: an overview. Can Med Res Opinion 1991: 12(8): 485-496.
12. Zanchetti A. Role of calcium antagonists in systemic hypertension. Am J Cardiol 1987; 59: 130B,
13. Marazzi P. PI A study to demonstrate the equivalence in efficacy and safety of once-daily nisoldipine CC and amlodipine in the treatment of mild to moderate hypertension. Ada Ther 1996 (In press).